Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Adamis Pharmaceuticl (ADMP)

Adamis Pharmaceuticl (ADMP)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Adamis Pharmaceuticals Provides Update on Litigation with kaleo Inc.

Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) ("Adamis") announced today that Adamis and kaleo Inc. agreed to settle all previously announced litigation between the parties, including the case filed...

ADMP : 1.17 (-7.87%)
Adamis Pharmaceuticals Provides Update on U.S. Retail Launch of SYMJEPI

Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) provided an update that Sandoz Inc. (Sandoz), a Novartis division, today announced the U.S. retail launch of SYMJEPI(TM) (epinephrine) 0.3 mg and 0.15...

ADMP : 1.17 (-7.87%)
Adamis Pharmaceuticals Provides Update on Litigation with kaleo Inc.

Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today provided an update on the litigation with kaleo Inc. regarding kaleo's claims of patent infringement relating to Adamis' higher dose naloxone injection...

ADMP : 1.17 (-7.87%)
Adamis Pharmaceuticals Announces Conditional Acceptance by FDA of Proprietary Name for Higher Dose Naloxone Product

Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) announced today conditional acceptance by the U.S. Food and Drug Administration (FDA) of the proposed brand name for the company's high dose naloxone product...

ADMP : 1.17 (-7.87%)
Adamis Pharmaceuticals (ADMP) Reports Q1 Loss, Misses Revenue Estimates

Adamis (ADMP) delivered earnings and revenue surprises of -11.76% and -17.48%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

ADMP : 1.17 (-7.87%)
Adamis: 1Q Earnings Snapshot

SAN DIEGO (AP) _ Adamis Pharmaceuticals Corp. (ADMP) on Thursday reported a loss of $8.9 million in its first quarter.

ADMP : 1.17 (-7.87%)
Adamis Pharmaceuticals Announces First Quarter 2019 Financial Results and Business Update

Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced financial results for the first quarter ended March 31, 2019 and provided a business update.

ADMP : 1.17 (-7.87%)
Adamis Pharmaceuticals Schedules First Quarter 2019 Earnings Conference Call and Business Update

Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) ("Adamis"), a specialty biopharmaceutical company primarily focused on developing and commercializing products in various therapeutic areas including respiratory...

ADMP : 1.17 (-7.87%)
Market Trends Toward New Normal in GrafTech International, Avinger, OraSure Technologies, Adamis Pharmaceuticals, Crinetics Pharmaceuticals, and Wayside Technology Group -- Emerging Consolidated Expectations, Analyst Ratings

In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of GrafTech International Ltd....

OSUR : 8.54 (+0.95%)
CRNX : 23.76 (-1.00%)
WSTG : 11.23 (+0.27%)
ADMP : 1.17 (-7.87%)
EAF : 10.64 (-0.19%)
AVGR : 2.37 (-2.47%)
Adamis Pharmaceuticals Announces 2018 Financial Results and Provides Business Update

Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced financial results for the year ended December 31, 2018 and provided a business update.

ADMP : 1.17 (-7.87%)
Adamis Pharmaceuticals Announces FDA Acceptance for Review of the New Drug Application of Its Higher Dose Naloxone Injection Product Candidate

Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) today announced that theU.S. Food and Drug Administration("FDA") has accepted for review the company's New Drug Application ("NDA") for its...

ADMP : 1.17 (-7.87%)
Adamis Pharmaceuticals (ADMP) May Report Negative Earnings: Know the Trend Ahead of Q4 Release

Adamis (ADMP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

ADMP : 1.17 (-7.87%)
Adamis Provides Regulatory Update on Sublingual Tadalafil

Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that it has received a Refusal to File letter from the United States Food and Drug Administration (FDA) regarding its New Drug Application...

ADMP : 1.17 (-7.87%)
Adamis Pharmaceuticals Publishes the Rationale for a Higher Dose Naloxone Product to Counter the Current Opioid Epidemic

Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) ("Adamis") announced today that the article entitled "Higher doses of naloxone are needed in the synthetic opioid era" has been published in the peer reviewed...

ADMP : 1.17 (-7.87%)
Adamis' Commercial Partner Launches SYMJEPI(TM) (epinephrine) in the US

Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that its marketing and commercial partner, Sandoz Inc. (Sandoz), a Novartis division, has launched SYMJEPI(TM) (epinephrine) 0.3 mg Injection...

ADMP : 1.17 (-7.87%)

Van Meerten Stock Picks

Leading Economic Indicator ALERT!
I very closely follow the Conference Board's Leading Economic Indicators.
IVV -1.75
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.

InsideFutures Commentary

InsideFutures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar